Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Rainer Krahl"'
Autor:
Thoralf Lange, Anja Edelmann, Udo Siebolts, Rainer Krahl, Claudia Nehring, Nadja Jäkel, Michael Cross, Jacqueline Maier, Dietger Niederwieser, Claudia Wickenhauser
Publikováno v:
Haematologica, Vol 98, Iss 5 (2013)
The risk profile and prognosis of patients with myelofibrosis is well described by the Dynamic International Prognostic Scoring System risk categorization. Allogeneic stem cell transplantation is considered for intermediate-2/high risk disease. Howev
Externí odkaz:
https://doaj.org/article/d877e4af67af4e2a88c24f6694acb97c
Autor:
Ann-Kathrin Eisfeld, Mark Westerman, Rainer Krahl, Sabine Leiblein, Uwe Gerd Liebert, Marianne Hehme, Daniel Teupser, Dietger Niederwieser, Haifa Kathrin Al-Ali
Publikováno v:
Advances in Hematology, Vol 2011 (2011)
Hepcidin is upregulated by inflammation and iron. Inherited (HFE genotype) and treatment-related factors (blood units (BU), Iron overload) affecting hepcidin (measured by C-ELISA) were studied in 42 consecutive patients with AML prior to and after al
Externí odkaz:
https://doaj.org/article/f16486f51ee0486e9987fbfcdc0876ba
Autor:
Dorle Messerer, Jutta Engel, Joerg Hasford, Markus Schaich, Gerhard Ehninger, Cristina Sauerland, Thomas Büchner, Andrea Schumacher, Rainer Krahl, Dietger Niederwieser, Jürgen Krauter, Arnold Ganser, Ursula Creutzig, Hartmut Döhner, Richard F. Schlenk
Publikováno v:
Haematologica, Vol 93, Iss 6 (2008)
Background The impact on quality of life of allogeneic stem cell transplantation or conventional chemotherapy in patients with acute myeloid leukemia remains unclear, mainly because of a lack of studies with long-term follow-up. The German AML-Interg
Externí odkaz:
https://doaj.org/article/6de3677511a546629b533ee896ab665c
Autor:
Markus Schaich, Richard F. Schlenk, Haifa K. Al-Ali, Hartmut Döhner, Arnold Ganser, Gerhard Heil, Thomas Illmer, Rainer Krahl, Jürgen Krauter, Cristina Sauerland, Thomas Büchner, Gerhard Ehninger
Publikováno v:
Haematologica, Vol 92, Iss 6 (2007)
Background and Objectives Trisomy 8 (+8) is among the commonest genetic aberrations seen in acute myeloid leukemia (AML). However, the prognostic significance of this aberration and the best consolidation strategy for patients with it are still not r
Externí odkaz:
https://doaj.org/article/a8674c320c0b430693b25f53f81518fa
Autor:
Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke, Georg Maschmeyer, Haifa Kathrin Al-Ali, Sebastian Schwind, Madlen Jentzsch, Michael Cross, Christoph Kahl, Hans-Heinrich Wolf, Herbert Sayer, Antje Schulze, Peter Dreger, Ute Hegenbart, Alwin Krämer, Christian Junghanss, Lars-Olof Mügge, Detlev Hähling, Carsten Hirt, Christian Späth, Norma Peter, Bernhard Opitz, Axel Florschütz, Kolja Reifenrath, Niklas Zojer, Sebastian Scholl, Wolfram Pönisch, Simone Heyn, Vladan Vucinic, Andreas Hochhaus, Carlo Aul, Aristoteles Giagounidis, Leopold Balleisen, Bernd Oldenkott, Peter Staib, Michael Kiehl, Wolfgang Schütte, Ralph Naumann, Hartmut Eimermacher, Bernd Dörken, Cristina Sauerland, Eva Lengfelder, Wolfgang Hiddemann, Bernhard Wörmann, Carsten Müller-Tidow, Hubert Serve, Christoph Schliemann, Rüdiger Hehlmann, Wolfgang E. Berdel, Markus Pfirrmann, Utz Krug, Verena S. Hoffmann
Publikováno v:
Annals of Hematology. 102:547-561
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study group arm
Autor:
Hans-Heinrich Wolf, Michael Cross, Kolja Reifenrath, Detlev Hähling, Rainer Krahl, Georg Maschmeyer, Thomas Fischer, Späth Christian, Christoph Kahl, Dietger Niederwieser, Christian Junghanss, Schmidt Volker, Antje Schulze, Thomas Heinicke, Niklas Zojer, Herbert G. Sayer, Haifa Kathrin Al-Ali, Axel Florschütz, Norma Peter, Andreas Hochhaus, Sebastian Scholl, Ute Hegenbart
Publikováno v:
Annals of Hematology
Ann Hematol
Ann Hematol
Relapse of acute leukemia is a frequent complication with uncertain outcome and poorly defined risk factors. From 1621 patients entered into two prospective clinical trials (AML02; n = 740 and AML04; n = 881), 74.2% reached complete remission (CR) 1
Autor:
Rainer Krahl, Thoralf Lange, Dietger Niederwieser, Christian Niederwieser, Ulrich von Grünhagen, Volker Lakner, Markus Pfirrmann, Kathleen Jentsch-Ullrich, Claudia Spohn, Michael Cross, Haifa Kathrin Al-Ali, Arthur Gil, Rüdiger Hehlmann, Christian Junghanss, Michael Assmann, Michael W. Deininger
Publikováno v:
Leukemia & Lymphoma. 61:2821-2830
The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML).AfterAdditive specific inhibition of CML cells by IM/HU was detectedIM/HU combination was more potent in selectively inhibiting
Autor:
Thomas Heinicke, Rainer Krahl, Christoph Kahl, Michael Cross, Sebastian Scholl, Hans‑Heinrich Wolf, Detlev Hähling, Ute Hegenbart, Norma Peter, Antje Schulze, Axel Florschütz, Volker Schmidt, Kolja Reifenrath, Niklas Zojer, Christian Junghanss, Herbert G. Sayer, Georg Maschmeyer, Christian Späth, Andreas Hochhaus, Thomas Fischer, Haifa Kathrin Al‑Ali, Dietger Niederwieser
Publikováno v:
Annals of Hematology. 100:2877-2878
Autor:
Christian Jakob, Christian Junghanss, Sebastian Schwind, Volker Schmidt, Niklas Zojer, Kolija Reifenrath, Andreas Hochhaus, Christoph Kahl, Dietger Niederwieser, Haifa Kathrin Al-Ali, Georg Maschmeyer, Thomas Heinicke, Herbert G. Sayer, Norma Peter, Rainer Krahl, Thomas Fischer, Sebastian Scholl, Axel Florschütz, Ute Hegenbart, Michael Cross, Hans-Heinrich Wolf, Christian Niederwieser
Publikováno v:
Blood. 134:1358-1358
Introduction: Outcome of patients (pts) with refractory AML or following relapse is considered dismal and usually reported as refractory/relapsed. Here we analyzed long term outcome of refractory and relapsing pts separately over a 10 year (y) period
Autor:
Marius Bill, Cornelia Becker, Rainer Krahl, Hannah Tessenow, Christian Pfrepper, Georg Franke, Sebastian Schwind, Vladan Vucinic, Madlen Jentzsch, Thomas Zehrfeld, Madlen Holzvogt, Dietger Niederwieser, Sabine Leiblein, Marc Andrea, Simone Heyn, Thoralf Lange, Bruno Holzvogt, Thomas Schliwa, Maik Schwarz, Wolfram Pönisch
Publikováno v:
Journal of cancer research and clinical oncology. 143(10)
Patients with light chain myeloma frequently have a light chain tubular cast nephropathy, which can lead to severe renal impairment. In the present retrospective study, bortezomib was combined with other active substances like bendamustine and predni